Biopharma looks beyond China to five alternative overseas markets amid rising geopolitical tensions
Geopolitical tensions between the United States and China are prompting biopharma companies to look beyond the Chinese market for growth.
China remains the leading destination, with licensing deals in the first half of 2026 topping $100 billion and involving majors such as Novartis, AstraZeneca and Eli Lilly.
The BIOSECURE Act, signed in December 2025, limits collaborations with Chinese firms flagged as national-security concerns, adding regulatory risk.
Consulting firm ZS says drugmakers are now evaluating established alternatives as China becomes more competitive and geopolitically complex.
The article highlights five overseas regions that could become new hubs for biotech investment.
This writeup was produced by pharmadog from original reporting by BioSpace.
Original headline: “Beyond China: Five other overseas destinations for biopharma dollars”
read at BioSpace ↗
comments(0)
5-min edit window · permanent after that